PPT-Castration-Sensitive Prostate Cancer: Navigating the Current Diagnostic and Treatment

Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC Supported by an educational grant from Astellas and Pfizer Inc EPISODE 3 Cora N Sternberg MD FACP Clinical Director . Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. Prostate Cancer Screening and Treatment. Mr Stephen Lindsay. Urological Surgeon. Bendigo. www.bendigourology.com. Prostate Cancer Risk Assessment. Prostate Cancer. Since the early 1990’s, Prostate Cancer has been the most commonly diagnosed cancer in Australian men (. CÉSAR DAVID VERA-DONOSO. Department. of . Urology. WHO IS IN THE LINE OF FIRE?. WE NEED TO COLLABORATE IN MANY FIELDS. WE NEED RELIABLE IMAGES TO TAKE DECISIONS. INCIDENCE. EUROPE. In Europe, . PCa. VeruInc The Prostate Cancer Company Novel MedicinesVeru Corporate PresentationJune 2020Thiscommunicationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995 Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, . Using PSMA-PET for accurate staging in biochemical recurrent metastatic prostate cancer. . Case courtesy of Associate Professor Yao ZHU, Fudan University, Shanghai Cancer Center. Photo by . Hobi. m. CSPC). 1. Neal Shore, MD, FACS. Carolina Urologic Research Center. Myrtle Beach, SC. Alicia Morgans, MD, MPH. Northwestern University. Chicago, IL. PROSTATE CANCER IS HORMONE DEPENDENT. 2. Huggins CB. Nobel lecture. Available from . Clinical implementation of testing and PARP. i. monotherapy, and the patient journey for prostate cancer patients. Dr Neal Shore. , . MD, FACS. Carolina Urologic Research Center and Chief Medical Officer for Genesis Care, USA. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical Program Director of Genitourinary Cancers, Inova . Schar. Cancer Institute. Associate Professor of Medicine, Virginia Commonwealth University. October 13, 2018. nm. CRPC patients and the healthcare team. GUIDE COMMUNICATION FRAMEWORK - . Part 3. Dr.. Jason Alcorn, D. . Nurs. , FHEA, MSc, BSc. Mid Yorkshire Hospitals NHS Trust, UK. NOVEMBER 2021. nmCRPC, non-metastatic castration-resistant prostate cancer. NASPCC 10-13-18. Ronald Chen, MD MPH. Associate Professor, Radiation Oncology. University of North Carolina – Chapel Hill. Associate Director, UNC Lineberger Comprehensive Cancer Center. Disclosures.